Phibro Animal Health Q4 FY2026 Results Show Solid Execution but Leverage and Regulatory Risk Persist

What happened

Phibro Animal Health reported fiscal 2026 fourth-quarter results, with full-year sales and adjusted EBITDA landing within the previously guided ranges, reflecting successful integration of the Zoetis medicated feed additive portfolio. Management highlighted continued growth in animal health and progress on de-leveraging, though net debt to EBITDA remains above 4x, limiting financial flexibility. The earnings call also addressed the ongoing FDA review of carbadox (Mecadox), which still poses a potential loss of ~$20 million in annual sales, with no clear resolution timeline. Margins were stable but not meaningfully expanded, as competitive pressures and higher interest expense from acquisition debt offset operational gains. The company initiated fiscal 2027 guidance, projecting modest sales growth and adjusted EBITDA expansion, but the market reaction was muted given valuation and balance sheet concerns.

Implication

The Q4 results confirm that the acquired Zoetis assets are contributing as planned, but the benefit is already reflected in the stock's premium valuation (P/E ~25x). Leverage remains elevated at over 4x net debt/EBITDA, and even with gradual de-leveraging, the company has limited capacity for further acquisitions or shareholder returns. The unresolved carbadox situation is a binary risk: an adverse FDA ruling could erase roughly $20 million in high-margin sales and pressure EBITDA by ~8-10%. Competitive dynamics in the animal health market are intense, with larger players like Zoetis and Elanco investing heavily in innovation, potentially eroding Phibro's niche advantages. Until we see clear evidence of margin expansion and a significant reduction in leverage, the risk/reward profile argues for avoiding new positions and holding only for those with a long-term horizon.

Thesis delta

Previous thesis was HOLD based on balanced risk/reward. After Q4 results, the thesis remains HOLD because execution is tracking plan but no meaningful de-risking has occurred. The de-leveraging pace is slower than hoped, and regulatory uncertainty persists, keeping the stock fairly valued rather than undervalued.